PSTI Pluristem Therapeutics Inc.

+0.11  (+3%)
Previous Close 3.51
Open 3.49
Price To Book 6.46
Market Cap 55,430,352
Shares 15,312,252
Volume 32,947
Short Ratio
Av. Daily Volume 79,296

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 EU data due 1H 2020; US data due 1H 2021.
PLX-PAD (stem cells)
Critical limb ischemia (CLI)
Phase 2 data released June 12, 2018 - primary endpoint met.
PLX-PAD (stem cells)
Intermittent claudication, or IC
Phase 1 DSMB approval given to continue to the final cohort - March 12, 2019.
Incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT)
Phase 3 data due 2H 2020.
Muscle injury following hip fracture

Latest News

  1. OFFICIAL CORRECTION-Pluristem gets positive results from radiation treatment trials
  2. Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
  3. The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug
  4. Pluristem Therapeutics’ CEO Issues Shareholders Update
  5. The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index
  6. Pluristem Announces One-for-Ten Reverse Split of its Common Shares
  7. What Kind Of Investor Owns Most Of Pluristem Therapeutics Inc. (NASDAQ:PSTI)?
  8. Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN
  9. Pluristem Therapeutics’ CEO Issues Shareholder Letter
  10. Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board
  11. Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product
  12. Pluristem Therapeutics Inc. (NASDAQ:PSTI): Are Analysts Optimistic?
  13. Lead Physicians in Pluristem’s Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper
  14. Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry
  15. Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe
  16. Does The Pluristem Therapeutics Inc. (NASDAQ:PSTI) Share Price Tend To Follow The Market?
  17. Pluristem Therapeutics Issues Shareholder Update
  18. Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million
  19. The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut
  20. Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock